...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics Proudly Supports Rare Disease Day ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications Calgary, Alberta--(N

lol Tada tada , for me you’ve always come across as someone close to or part of the Kool aid gang, never being to harsh on your leader , towing the line so to speak, ya know, so you can still hear the whispers. Perhaps you’re sitting on something again thats emboldening you to go off on these unusually long winded posts. You’ve shown plenty of patience , understanding & excuses for the leader. Consider using the ignore button for those who don’t.

Glta 
Share
New Message
Please login to post a reply